Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: A PLCO Study

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 207-214

  Shebl, F M ^a,b   Sakoda, L C ^a,c   Black, A ^a   Koshiol, J ^a   Andriole, G L ^d   Grubb, R ^d   Church, T R ^e   Chia, D ^f   Zhou, C ^a,g   Chu, L W ^a   Huang, W Y ^a   Peters, U ^h   Kirsh, V A ^i,j   Chatterjee, N ^a   Leitzmann, M F ^a,k   Hayes, R B ^k   Hsing, A W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g GEORGE WASHINGTON UNIVERSITY   (United States)

^h USA   (United States)

ⁱ CANCER CARE ONTARIO   (Canada)

^j UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

cyclooxgenase; non steroidal anti inflammatory drugs; Prostate cancer

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; BAYER; FINASTERIDE; IBUPROFEN; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTHRITIS; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; DRUG USE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSTATE CANCER; SELF REPORT; STATISTICAL ANALYSIS;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; HUMANS; IBUPROFEN; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK; RISK REDUCTION BEHAVIOR;

EID: 84862989872     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.227     Document Type: Article

References (65)

1. Andersen PK (1993) Statistical Models Based on Counting Processes, Springer-Verlag: New York
2. Andrews J, Djakiew D, Krygier S, Andrews P (2002) Superior effectiveness of ibuprofen compared with other NSAIDs for reducing the survival of human prostate cancer cells. Cancer Chemother Pharmacol 504: 277-284
3. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60(16): 4629-4637 (Pubitemid 32103650)
4. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C (2006) Aspirin and the risk of prostate cancer. Eur J Cancer Prev 15(1): 43-45 (Pubitemid 43048741)
5. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E (2010) Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev 19(12): 3185-3188
6. Campbell CL, Smyth S, Montalescot G, Steinhubl SR (2007) Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 297(18): 2018-2024 (Pubitemid 46740354)
7. Cheng I, Liu X, Plummer SJ, Krumroy LM, Casey G, Witte JS (2007) COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Br J Cancer 97(4): 557-561 (Pubitemid 47258446)
8. Cheng I, Plummer SJ, Jorgenson E, Liu X, Rybicki BA, Casey G, Witte JS (2008) 8q24 and prostate cancer: association with advanced disease and meta-analysis. Eur J Hum Genet 16(4): 496-505 (Pubitemid 351420383)
9. Chu LW, Reichardt JK, Hsing AW (2008) Androgens and the molecular epidemiology of prostate cancer. Curr Opin Endocrinol Diabetes Obes 15(3): 261-270 (Pubitemid 351595192)
10. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E (2006) Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 12(2): 130-135
11. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Tubaro A (2011) The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 60(1): 106-117
12. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL (2011) Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 128(10): 2444-2452
13. Fleming ID, American Joint Committee on Cancer, American Cancer Society, American College of Surgeons (1997) AJCC Cancer Staging Manual. 5th edn, Lippincott-Raven: Philadelphia
14. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Caan BJ (2007) Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev 16(11): 2218-2225 (Pubitemid 351196352)
15. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH (2003) A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 88(5): 684-688 (Pubitemid 36411444)
16. Garcia Rodriguez LA, Gonzalez-Perez A (2004) Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 13(4): 649-653 (Pubitemid 38737903)
17. Gohagan JK, Prorok PC, Hayes RB, Kramer BS (2000) The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21(6 Suppl): 251S-272S
18. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1): 73-78 (Pubitemid 30004877)
19. Habel LA, Zhao W, Stanford JL (2002) Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control 13(5): 427-434 (Pubitemid 34666598)
20. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11: 1388-1413 (Pubitemid 43253429)
21. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275(15): 11397-11403 (Pubitemid 30212792)
22. Jacobs EJ, Newton CC, Stevens VL, Gapstur SM (2011) A large cohort study of long-term acetaminophen use and prostate cancer incidence. Cancer Epidemiol Biomarkers Prev 20(7): 1322-1328
23. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE (2007) Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 16(11): 2213-2217 (Pubitemid 351196351)
24. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ (2005) A large cohort study of aspirin and other nonsteroidal antiinflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 97(13): 975-980 (Pubitemid 41430563)
25. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8): 608-615 (Pubitemid 47073542)
26. Kamijo T, Sato T, Nagatomi Y, Kitamura T (2001) Induction of apoptosis by cyclooxygenase-2 inhibitors in prostate cancer cell lines. Int J Urol 8(7): S35-S39 (Pubitemid 34225135)
27. Korn EL, Graubard BI, Midthune D (1997) Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 145(1): 72-80 (Pubitemid 27009060)
28. Lee LM, Pan CC, Cheng CJ, Chi CW, Liu TY (2001) Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Res 21(2B): 1291-1294
29. Leitzmann MF, Ahn J, Albanes D, Hsing AW, Schatzkin A, Chang SC, Andriole GL (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control 19(10): 1267-1276
30. Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E (2002) Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1): 1108-1111 (Pubitemid 35192666)
31. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS (2006) Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol 164(10): 984-989 (Pubitemid 44729840)
32. Liu XH, Kirschenbaum A, Yao S, Lee R, Holland JF, Levine AC (2000) Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 164(3 Pt 1): 820-825 (Pubitemid 30637640)
33. Liu XH, Yao S, Kirschenbaum A, Levine AC (1998) NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 58(19): 4245-4249 (Pubitemid 28450018)
34. Lloyd Jr FP, Slivova V, Valachovicova T, Sliva D (2003) Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol 23(5): 1277-1283
35. Lucia MS, Torkko KC (2004) Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 1712(Pt 2): S30-S34
36. Madaan S, Abel PD, Chaudhary KS, Hewitt R, Stott MA, Stamp GW, Lalani EN (2000) Cytoplasmic induction and over-expression of cyclooxygenase-2 in human prostate cancer: implications for prevention and treatment. BJU Int 86(6): 736-741
37. Mahmud S, Franco E, Aprikian A (2004) Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and metaanalysis. Br J Cancer 90(1): 93-99 (Pubitemid 38174945)
38. Mahmud SM, Franco EL, Aprikian AG (2010) Use of nonsteroidal antiinflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 127(7): 1680-1691
39. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Aprikian AG (2011) Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 6(1): e16412
40. Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG (2006) Nonsteroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev 15(2): 158-164 (Pubitemid 44145601)
41. Murad AS, Down L, Davey Smith G, Donovan JL, Athene Lane J, Hamdy FC, Martin RM (2011) Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). Int J Cancer 128(6): 1442-1448
42. Nelson JE, Harris RE (2000) Inverse association of prostate cancer and nonsteroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7(1): 169-170
43. Norrish AE, Jackson RT, McRae CU (1998) Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer 77(4): 511-515 (Pubitemid 28340895)
44. O'Neill GP, Ford-Hutchinson AW (1993) Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330(2): 156-160 (Pubitemid 23265121)
45. Paganini-Hill A, Chao A, Ross RK, Henderson BE (1989) Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 299(6710): 1247-1250 (Pubitemid 19280046)
46. Perron L, Bairati I, Moore L, Meyer F (2003) Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 106(3): 409-415 (Pubitemid 36870405)
47. Platz EA, De Marzo AM (2004) Epidemiology of inflammation and prostate cancer. J Urol 171(2 Pt 2): S36-S40 (Pubitemid 38090420)
48. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E (2006) Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 98(24): 1819-1825 (Pubitemid 46017933)
49. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Carter HB (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev 14(2): 390-396 (Pubitemid 40270102)
50. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Gohagan JK (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 21(6 Suppl): 273S-309S
51. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Furberg CD (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47(6): 749-754 (Pubitemid 29266647)
52. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ (2002) A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 77(3): 219-225 (Pubitemid 34177596)
53. Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Stanford JL (2010) Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol 172(5): 578-590
54. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2): 138-146 (Pubitemid 24073387)
55. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1): 10-29
56. Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69: 145-182
57. Soni A (2007) Aspirin Use among the Adult US Noninstitutionalized Population, with and without Indicators of Heart Disease, 2005. Statistical Brief #179 July from http://www.meps.ahrq.gov/mepsweb/data-files/publications/ st179/stat179.pdf
58. Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Baron JA (2003) Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer 88(11): 1687-1692 (Pubitemid 36760410)
59. Stock D, Groome PA, Siemens DR (2008) Inflammation and prostate cancer: a future target for prevention and therapy? Urol Clin North Am 35(1): 117-130 vii (Pubitemid 350176596)
60. Taylor ML, Wells BJ, Smolak MJ (2008) Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 17(3): 259-268 (Pubitemid 351549667)
61. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P (2001) Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urol Res 29(1): 23-28
62. Weiss NS (2003) Adjusting for screening history in epidemiologic studies of cancer: why, when, and how to do it. Am J Epidemiol 157(11): 957-961 (Pubitemid 36628796)
63. Willett W, Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. Am J Epidemiol 124(1): 17-27 (Pubitemid 16095831)
64. Witte JS (2007) Multiple prostate cancer risk variants on 8q24. Nat Genet 39(5): 579-580 (Pubitemid 46676095)
65. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Isaacs WB (2001) Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61(24): 8617-8623 (Pubitemid 34013865)